Literature DB >> 10858373

Combination antifungal therapy in treatment of murine pulmonary mucormycosis: roles of quinolones and azoles.

A M Sugar1, X P Liu.   

Abstract

Amphotericin B is the only recognized antifungal used in the treatment of mucormycosis. In this study, we evaluated various combinations of amphotericin B, fluconazole, and trovafloxacin or ciprofloxacin in the treatment of murine pulmonary mucormycosis. The combination of fluconazole and a quinolone has a marked effect on the outcome of murine pulmonary mucormycosis. Even though we did not optimize therapy with the drugs, these experiments suggest that azoles, especially fluconazole, in combination with either trovafloxacin or ciprofloxacin were effective in the treatment of this aggressive mycosis in the mouse model.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10858373      PMCID： PMC90004          DOI： 10.1128/AAC.44.7.2004-2006.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  6 in total

1.  Successful treatment of disseminated mucormycosis with liposomal amphotericin B and surgery in a child with leukemia.

Authors:  S Maury; T Leblanc; M Feuilhade; J M Molina; G Schaison
Journal:  Clin Infect Dis       Date:  1998-01       Impact factor: 9.079

2.  Effectiveness of quinolone antibiotics in modulating the effects of antifungal drugs.

Authors:  A M Sugar; X P Liu; R J Chen
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

3.  Rhinocerebral mucormycosis: evolution of the disease and treatment options.

Authors:  K L Peterson; M Wang; R F Canalis; E Abemayor
Journal:  Laryngoscope       Date:  1997-07       Impact factor: 3.325

4.  Fluconazole in the treatment of three cases of mucormycosis.

Authors:  R Koçak; T Tetiker; M Koçak; F Başlamişli; S Zorludemir; G Gönlüşen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-06       Impact factor: 3.267

5.  Treatment of murine pulmonary mucormycosis with SCH 42427, a broad-spectrum triazole antifungal drug.

Authors:  L Z Goldani; A M Sugar
Journal:  J Antimicrob Chemother       Date:  1994-02       Impact factor: 5.790

6.  Rhinocerebral mucormycosis: changing patterns of disease.

Authors:  E S Nussbaum; W A Hall
Journal:  Surg Neurol       Date:  1994-02
  6 in total
  10 in total

Review 1.  Antifungal activity of nonantifungal drugs.

Authors:  J Afeltra; P E Verweij
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-06-26       Impact factor: 3.267

2.  In vitro susceptibilities of zygomycetes to combinations of antimicrobial agents.

Authors:  Eric Dannaoui; Javier Afeltra; Jacques F G M Meis; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

Review 3.  Combination antifungal therapy.

Authors:  Melissa D Johnson; Conan MacDougall; Luis Ostrosky-Zeichner; John R Perfect; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

4.  In vitro interactions between antifungals and immunosuppressive drugs against zygomycetes.

Authors:  Eric Dannaoui; Patrick Schwarz; Olivier Lortholary
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191

5.  Efficacy of antifungal therapy in a nonneutropenic murine model of zygomycosis.

Authors:  Eric Dannaoui; Johan W Mouton; Jacques F G M Meis; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

Review 6.  Current Treatment Options for COVID-19 Associated Mucormycosis: Present Status and Future Perspectives.

Authors:  Yasasve Madhavan; Kadambari Vijay Sai; Dilip Kumar Shanmugam; Aashabharathi Manimaran; Karthigadevi Guruviah; Yugal Kishore Mohanta; Divyambika Catakapatri Venugopal; Tapan Kumar Mohanta; Nanaocha Sharma; Saravanan Muthupandian
Journal:  J Clin Med       Date:  2022-06-23       Impact factor: 4.964

7.  Posaconazole combined with amphotericin B, an effective therapy for a murine disseminated infection caused by Rhizopus oryzae.

Authors:  M Mar Rodríguez; Carolina Serena; Marçal Mariné; F Javier Pastor; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2008-08-11       Impact factor: 5.191

8.  Activity of posaconazole in treatment of experimental disseminated zygomycosis.

Authors:  Eric Dannaoui; Jacques F G M Meis; David Loebenberg; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

Review 9.  Animal models of zygomycosis--Absidia, Rhizopus, Rhizomucor, and Cunninghamella.

Authors:  K Kamei
Journal:  Mycopathologia       Date:  2001       Impact factor: 3.785

Review 10.  Combination Antifungal Therapy: A Review of Current Data.

Authors:  Marco Campitelli; Nabil Zeineddine; Ghassan Samaha; Stephen Maslak
Journal:  J Clin Med Res       Date:  2017-04-26
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.